Bringing the Oncology Community Together
Novel Therapies on the Horizon in AML
Treatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care.
Pertuzumab Use Continues to Expand in Breast Cancer
Treatment strategies that incorporate pertuzumab (Perjeta) continue to evolve as more clinical trial data becomes available.
UCLA Researcher Provides Insight Into the Impact of Pembrolizumab in Melanoma
To gain further insight into the approval of pembrolizumab, OncLive interviewed John Glaspy, MD, MPH, from the Jonsson Comprehensive Cancer Center at UCLA, where research into the novel drug was conducted.
Ramucirumab Improves Survival in mCRC
The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.
FDA Approves Pre-Chemo Enzalutamide for mCRPC
The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Rosenberg Sees New Milestone in Latest CAR Findings
Steven A. Rosenberg, MD, PhD, discusses the implications of responses to the CAR T-cell therapy KTE-C19, particularly among patients with chemotherapy-refractory diffuse large B-cell lymphomas.
New ASCO/CCO mCRPC Treatment Guideline Incorporates Latest Approved Drugs
ASCO and CCO have released an updated guideline focused on the treatment of men with mCRPC that incorporates information about 6 recently approved drugs that have significantly changed the therapeutic landscape.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.